维普期刊资源整合服务平台（V6.5）

78篇 您的检索式：作者名="LEMINEN H"

选中清除导出查看参考文献查看引证文献引用追踪共4页首页上一页第1页下一页末页 /4 跳转

	题名	作者	年代	出处	被引量
1	Ezrin immunoreacflvlty in relation to survival in serious ovarian patients显示文摘	Moilanen J Lassus H Leminen A et at	2003	Gynecol oneol2003，90，2：	1
2	Gene amplification,mutation and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma显示文摘	Lassus H Sihto H Leminen A	2006	J Mol Med2006，84，8：	1
3	Ezrin immunoreactlvlty in relation to survival in serious ovarian patients显示文摘	Moilanen J Lassus H Leminen A	2003	Gynecol oneol2003，90，2：	1
4	Ezrin immunoreaetivity in relationship to survival in serous ovarian carcinoma patients显示文摘	Moilanen J Lassus H Leminen A	2003	Gynecol Oncol2003，90，2：	1
5	ERBB2 amplification is superior to protein expression status in predicting patient outcome in serous ovarian carcinoma显示文摘	Lassus H Leminen A Vayrynen A	2004	Gynecol Oncol2004，92，1：	1
6	Tranexamic acid for the treatment of heavy menstrual bleeding: efficacy and safety显示文摘	LEMINEN H HURSKAINEN R	2012	Int J Womens Health2012，4，：	1
7	Ezrin immunoreactivity in relation to survival in serous ovarian carcinoma patients显示文摘	LASSUS H LEMINEN A	2003	Gynecol Oncol2003，90，2：	1
8	Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous o- varian carcinoma显示文摘	Lassus H Sihto H Leminen A	2006	J Mol Med2006，84，8：	1
9	Pharmacokineticsof 10mg of mifepristoner显示文摘	Leminen R Ranta S Von Hertzen H	2003	Contraception2003，68，6：	1
10	Ezrin immunoreactivity in relation to survival in serous ovarian carcinoma patients显示文摘	MOILANEN J LASSUS H LEMINEN A	2003	Gynecol Oncol2003，90，2：	1
11	Ezrin immunore- activity in relation to survival in serous ovarian carcinoma patienls显示文摘	Moilanen J Lassus H Leminen A	2003	Gynecol Oncol2003，90，2：	1
12	Ezrin immunoreactivity in relation to survival in serous ovarian carcinoma patients 显示文摘	Moilanen J Lassus H Leminen A	2003	Gynecol Oncol2003，90，2：	1
13	Ezrin immu- noreactivity in relation to survival in serous ovarian car- cinoma patients 显示文摘	Moilanen J Lassus H Leminen A	2003	Gynecol Oncol2003，90，2：	1
14	Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma 显示文摘	Lassus H Sihto H Leminen A	2006	J Mol Med2006，84，8：	1
15	Ezrin immunoreactivity in relation to survival in serous ovarian carcinoma patients显示文摘	Moilanen J Lassus H Leminen A	2003	Gynecol Oncol2003，90，2：	1
16	Aurora-A overexpression and aneuploidy predict poor outcome in serous ovarian carcinoma显示文摘	Lassus H Staff S Leminen A		0，，01：	1
17	Ezrin immunoreaetivity in re- lationship to survival in serous ovarian patients 显示文摘	Moilanen J Laggus H Leminen A	2003	Gynecol Oneol2003，90，2：	1
18	Ezrin immunoreactivity in relation to survival in serous ovarian carcinoma patients显示文摘	Moilanen J Lassus H Leminen A	2003	Gynecol Oncol2003，90，2：	1
19	ERBB2 amplification is superior to protein expression status in predicting patient outcome in serous ovarian carcinoma 显示文摘	Lassus H Leminen A Vayrynen A	2004	Gynecol Oncol2004，92，1：	1
20	Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma 显示文摘	Lassus H Sihto H Leminen A	2006	J Mol Med2006，84，8：	1

返回顶部每页显示：

共4页首页上一页第1页下一页末页 /4 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示